Evidence map›Paper›PMID 29337963›Full record

ArticleBritish journal of cancer2018

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Rastislav Bahleda, Andrea Varga, Yann Bergé, Jean-Charles Soria, David Schnell, Inga Tschoepe, Martina Uttenreuther-Fischer, Jean-Pierre Delord

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Targeting HER2 genomic alterations in non-small cell lung cancer.Journal of the National Cancer Center · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Rastislav BahledaDépartement d'Innovation Thérapeutique et d'Essais Précoces, Institut Gustave Roussy, 114 Rue Edouard Vaillaint, Villejuif 94805, France.
Andrea VargaDépartement d'Innovation Thérapeutique et d'Essais Précoces, Institut Gustave Roussy, 114 Rue Edouard Vaillaint, Villejuif 94805, France.
Yann BergéDepartment of Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse 31100, France.
Jean-Charles SoriaDépartement d'Innovation Thérapeutique et d'Essais Précoces, Institut Gustave Roussy, 114 Rue Edouard Vaillaint, Villejuif 94805, France.
David SchnellTranslational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach 88397, Germany.
Inga TschoepeBoehringer Ingelheim France S.A.S., Reims 51100, France.
Martina Uttenreuther-FischerTA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach 88397, Germany.
Jean-Pierre DelordDepartment of Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse 31100, France.
Institut Gustave Roussy · FRBoehringer Ingelheim (Germany) · DEInstitut Claudius Regaud · FRBoehringer Ingelheim (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis phase Ib study evaluated afatinib plus vinorelbine in patients with advanced solid tumours overexpressing epidermal growth factor receptor (EGFR) and/or human EGFR 2 (HER2).

methodsMaximum tolerated doses (MTDs) were determined for afatinib (20, 40 or 50 mg, once daily) combined with standard intravenous vinorelbine (part A; 25 mg m

resultsThe afatinib MTD was 40 mg with intravenous (MTD

conclusionsAfatinib in combination with intravenous or oral vinorelbine demonstrated a manageable safety profile and antitumour activity at the MTD of 40 mg per day.

Indexed as

Administration, OralAdultAfatinibAgedAntineoplastic Combined Chemotherapy ProtocolsAstheniaDiarrheaErb-b2 Receptor Tyrosine KinasesFebrile NeutropeniaFemaleHumansInfusions, IntravenousMaleMaximum Tolerated DoseMiddle AgedNauseaAfatinibERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesVinorelbine

Identifiers

PMID29337963
PMCPMC5808039
OpenAlexW2782604699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.